INCY
Incyte Corporation
NASDAQ: INCY · HEALTHCARE · BIOTECHNOLOGY
$121.47
-1.47% today
Updated 2026-09-11
Market cap
$25.22B
P/E ratio
15.85
P/S ratio
4.33x
EPS (TTM)
$7.85
Dividend yield
—
52W range
$81 – $133
Volume
1.6M
Incyte Corporation (INCY) Insider transactions
Net insider activity
Net buying (527,448 shares)
Buy transactions
56
Sell transactions
44
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-25 | BASI, RAMITPAL K | EVP, Human Resources | Sale | 504 | $129.72 | $65378.88 |
| 2026-08-19 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 10,801 | $125.56 | $1.36M |
| 2026-08-12 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 10,803 | $120.04 | $1.30M |
| 2026-08-05 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,207 | — | — |
| 2026-08-05 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,207 | $123.99 | $273645.93 |
| 2026-08-05 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 10,640 | $122.69 | $1.31M |
| 2026-08-03 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 6,055 | — | — |
| 2026-08-03 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 6,055 | $120.43 | $729203.65 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 9,459 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 3,148 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 3,023 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,918 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,864 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,709 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,623 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,293 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,284 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,072 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 1,643 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 1,642 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 326 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 85 | — | — |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 14,661 | $119.46 | $1.75M |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 9,459 | $72.27 | $683601.93 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 6,171 | $119.43 | $737002.53 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 5,332 | $119.42 | $636747.44 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 4,695 | $119.39 | $560536.05 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 3,148 | $68.62 | $216015.76 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 3,023 | $83.20 | $251513.60 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 2,918 | $61.18 | $178523.24 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 2,864 | $77.67 | $222446.88 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 2,709 | $61.76 | $167307.84 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 2,623 | $74.78 | $196147.94 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 2,293 | $90.56 | $207654.08 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 2,284 | $64.25 | $146747.00 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 2,187 | $119.47 | $261280.89 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 2,072 | $71.93 | $149038.96 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 1,643 | $80.50 | $132261.50 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 1,642 | $85.01 | $139586.42 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 326 | $105.43 | $34370.18 |
| 2026-07-31 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 85 | $106.47 | $9049.95 |
| 2026-07-31 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 15,888 | $119.70 | $1.90M |
| 2026-07-23 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Buy | 8,999 | — | — |
| 2026-07-23 | MORRISSEY, MICHAEL JAMES | EVP, Head of Tech. Operations | Buy | 6,426 | — | — |
| 2026-07-23 | HEESON, LEE | EVP, Head of Incyte Intl | Buy | 13,498 | — | — |
| 2026-07-23 | HEESON, LEE | EVP, Head of Incyte Intl | Buy | 15,423 | — | — |
| 2026-07-16 | TRAY, THOMAS | Principal Accounting Officer | Buy | 4,079 | — | — |
| 2026-07-16 | TRAY, THOMAS | Principal Accounting Officer | Buy | 2,834 | — | — |
| 2026-07-16 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Buy | 24,496 | — | — |
| 2026-07-16 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Buy | 42,298 | — | — |
| 2026-07-16 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Buy | 9,798 | — | — |
| 2026-07-16 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 1,877 | $114.73 | $215348.21 |
| 2026-07-16 | MEURY, WILLIAM | Director, Chief Executive Officer | Buy | 80,421 | — | — |
| 2026-07-16 | MEURY, WILLIAM | Director, Chief Executive Officer | Buy | 77,148 | — | — |
| 2026-07-16 | MEURY, WILLIAM | Director, Chief Executive Officer | Buy | 26,807 | — | — |
| 2026-07-16 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 14,790 | — | — |
| 2026-07-16 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 25,538 | — | — |
| 2026-07-16 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Buy | 5,916 | — | — |
| 2026-07-16 | ISSA, MOHAMED KHAIRIE | EVP, Head of U.S. Commercial | Buy | 19,643 | — | — |
| 2026-07-16 | ISSA, MOHAMED KHAIRIE | EVP, Head of U.S. Commercial | Buy | 33,918 | — | — |
| 2026-07-16 | ISSA, MOHAMED KHAIRIE | EVP, Head of U.S. Commercial | Buy | 7,857 | — | — |
| 2026-07-16 | ISSA, MOHAMED KHAIRIE | EVP, Head of U.S. Commercial | Sale | 1,093 | $115.01 | $125705.93 |
| 2026-07-16 | HOFFMAN, RICHARD A. | EVP & General Counsel | Buy | 18,487 | — | — |
| 2026-07-16 | HOFFMAN, RICHARD A. | EVP & General Counsel | Buy | 31,923 | — | — |
| 2026-07-16 | HOFFMAN, RICHARD A. | EVP & General Counsel | Buy | 7,395 | — | — |
| 2026-07-16 | GARDNER, DAVID H | EVP, Chief Strategy Officer | Buy | 18,487 | — | — |
| 2026-07-16 | GARDNER, DAVID H | EVP, Chief Strategy Officer | Buy | 31,923 | — | — |
| 2026-07-16 | GARDNER, DAVID H | EVP, Chief Strategy Officer | Buy | 7,395 | — | — |
| 2026-07-16 | CAGNONI, PABLO J | President, Global Head of R&D | Buy | 33,508 | — | — |
| 2026-07-16 | CAGNONI, PABLO J | President, Global Head of R&D | Buy | 57,861 | — | — |
| 2026-07-16 | CAGNONI, PABLO J | President, Global Head of R&D | Buy | 13,403 | — | — |
| 2026-07-16 | BASI, RAMITPAL K | EVP, Human Resources | Buy | 12,479 | — | — |
| 2026-07-16 | BASI, RAMITPAL K | EVP, Human Resources | Buy | 21,548 | — | — |
| 2026-07-16 | BASI, RAMITPAL K | EVP, Human Resources | Buy | 4,991 | — | — |
| 2026-07-15 | TRAY, THOMAS | Principal Accounting Officer | Sale | 1,098 | $115.09 | $126368.82 |
| 2026-07-15 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 28,237 | $113.05 | $3.19M |
| 2026-07-15 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 3,088 | $115.09 | $355397.92 |
| 2026-07-15 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 1,512 | $115.09 | $174016.08 |
| 2026-07-15 | ISSA, MOHAMED KHAIRIE | EVP, Head of U.S. Commercial | Sale | 1,099 | $115.09 | $126483.91 |
| 2026-07-15 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 4,950 | $115.09 | $569695.50 |
| 2026-07-14 | TRAY, THOMAS | Principal Accounting Officer | Sale | 692 | $114.88 | $79496.96 |
| 2026-07-14 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 21,830 | $114.88 | $2.51M |
| 2026-07-14 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 437 | $114.88 | $50202.56 |
| 2026-07-14 | CAGNONI, PABLO J | President, Global Head of R&D | Sale | 17,969 | $114.88 | $2.06M |
| 2026-07-02 | TRAY, THOMAS | Principal Accounting Officer | Sale | 477 | $116.86 | $55742.22 |
| 2026-07-02 | STEIN, STEVEN H | CMO & Head of Late-Stage Dev. | Sale | 2,177 | $116.86 | $254404.22 |
| 2026-07-02 | MEURY, WILLIAM | Director, Chief Executive Officer, President | Sale | 4,779 | $116.86 | $558473.94 |
| 2026-07-02 | MAYES, PATRICK A | EVP & Chief Scientific Officer | Sale | 350 | $116.86 | $40901.00 |
| 2026-06-30 | HARRIGAN, EDMUND | Director | Buy | 255 | $113.36 | $28906.80 |
| 2026-06-30 | CLANCY, PAUL J | Director | Buy | 252 | $113.36 | $28566.72 |
| 2026-06-30 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 400 | — | — |
| 2026-06-08 | HIGH, KATHERINE A | Director | Buy | 6,111 | — | — |
| 2026-06-08 | HIGH, KATHERINE A | Director | Buy | 1,642 | — | — |
| 2026-06-08 | HARRIGAN, EDMUND | Director | Buy | 6,111 | — | — |
| 2026-06-08 | HARRIGAN, EDMUND | Director | Buy | 1,642 | — | — |
| 2026-06-08 | FOUSE, JACQUALYN A | Director | Buy | 6,111 | — | — |
| 2026-06-08 | FOUSE, JACQUALYN A | Director | Buy | 1,642 | — | — |
| 2026-06-08 | CLANCY, PAUL J | Director | Buy | 6,111 | — | — |
| 2026-06-08 | CLANCY, PAUL J | Director | Buy | 1,642 | — | — |
| 2026-06-08 | BRAWLEY, OTIS W | Director | Buy | 6,111 | — | — |
Frequently asked questions
Are INCY insiders buying or selling?
Over the transactions on record, INCY insiders have been net buyers, with about $21.37M in stock sold across 44 sales, against 16 open-market purchases.
Does insider selling at INCY mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which INCY insiders are selling the most?
Recent selling is concentrated in a few names. CAGNONI, PABLO J accounts for the largest share on record, with about $8.49M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.